Triumph Capital Management
IGC icon

Triumph Capital Management’s IGC Pharma IGC Stock Holding History

Triumph Capital Management’s Portfolio IGC Stock Details IGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1 Hold
2
– – ﹤0.01% 1906
2026
Q2 		$1 Hold
2
– – ﹤0.01% 1861
2026
Q1 		$1 Hold
2
– – ﹤0.01% 1836
2025
Q4 		$1 Buy
+2
New +$1 ﹤0.01% 1769

Other funds holding IGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
AdvisorShares Investments
AdvisorShares Investments Bethesda, Maryland $796M AUM 17.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
LC
Lawood & Co Williamsport, Pennsylvania $145M AUM 29.71% 1-Year Est. Return
Dearborn Partners
Dearborn Partners Chicago, Illinois $1.65B AUM 8.8% 1-Year Est. Return

Triumph Capital Management's IGC Position: Q3 2026 in Review

Triumph Capital Management held its IGC Pharma (IGC) position steady in Q3 2026 at 2 shares worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #1906.

Triumph Capital Management first reported a position in IGC in Q4 2025 and has held it in 4 quarters since. 24 funds tracked by Wall St. Rank hold IGC as of Q3 2026.

  • Triumph Capital Management held 2 shares of IGC Pharma worth $1 as of Q3 2026.
  • Triumph Capital Management left its IGC Pharma share count unchanged in Q3 2026.
  • IGC Pharma made up ﹤0.01% of Triumph Capital Management's portfolio in Q3 2026, its #1906 holding.
  • Triumph Capital Management first reported a position in IGC Pharma in Q4 2025 and has held it in 4 quarters since.
  • 24 funds tracked by Wall St. Rank held IGC Pharma as of Q3 2026.

Based on Triumph Capital Management's 13F filing for Q3 2026, filed 14 Oct 2026.